Accumulators in (and Beyond) Generic Groups: Non-trivial Batch Verification Requires Interaction

2020 ◽  
pp. 77-107
Author(s):  
Gili Schul-Ganz ◽  
Gil Segev
Keyword(s):  
Batch Verification ◽  
Generic Groups

System of generic groups in mealybugs (Homoptera: Coccinea: Pseudococcidae)

2015 ◽  
Vol 24 (2) ◽  
pp. 236-259 ◽  
Author(s):  
I.A. Gavrilov-Zimin
Keyword(s):  
Taxonomic Revision ◽  
Generic Rank ◽  
The World ◽  
Generic Groups ◽  
World Fauna

The paper provides a brief conspectus of the system of morphological generic groups, elaborated earlier by the author basing on the total taxonomic revision of Palaearctic mealybugs. Here the system is complemented by the analysis of all 249 genera of the world fauna. Borders of two generic groups are reconsidered and two else groups (with mainly Oriental and Australasian genera) are included in the system. Main taxonomic characters of generic rank are discussed and illustrated.

scholarly journals SOME GENERIC GROUPS IN THE MALLOPHAGAN FAMILY MENOPONIDÆ

1916 ◽  
Vol 48 (9) ◽  
pp. 301-311 ◽  
Author(s):  
G. F. Ferris
Keyword(s):  
Generic Groups

New genera and species of Ptiliini (Coleoptera: Ptiliidae) with a tribal revision and key to genera

2021 ◽  
pp. 1-59
Author(s):  
Michael Darby
Keyword(s):  
New Species ◽  
New Genera ◽  
The Future ◽  
Generic Groups

Abstract The list of genera in the polyphyletic tribe Ptiliini, used as a dumping ground for difficult genera of Ptiliidae by several generations of Coleopterists, is brought up to date with recent additions and omissions, and figures and a key to the genera are provided to aid their determination. 29 new species and 3 new genera are added. It was hoped to be able to determine some generic groups within the tribe but that work must depend on further cladistical and DNA research in the future. The new genera are Cingulum gen.n., Iloptila gen.n. and Numa gen.n. and the new species are Actidium cooteri sp.n., A. minimum sp.n., A. nigrum sp.n., Cingulum orsippus gen.n. sp.n., Dipentium bicolor sp.n., D. punctissimum sp.n., D. spinosum sp.n., Gomyella intricata sp.n., G. nicoya sp.n., G. profunda sp.n., G. tripla sp.n., Greensladella cicra sp.n., G. similata sp.n., Iloptila modica gen.n. sp.n., Micridium circulatum sp.n., M. dembickyi sp.n., M. hirsutum sp.n., M. juara sp.n., M. novum sp.n., Millidium karnatakense sp.n., Numa carmen gen.n. sp.n., Ptiliodes kanchiporam sp.n., Ptiliola bennetti sp.n., P. nigra sp.n., P. peruviensis sp.n., Ptilium lisae sp.n., P. longum sp.n., P. pallidulum sp.n. and P. piceum sp.n.

scholarly journals Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4156-4156
Author(s):  
Ekin Kircali ◽  
Guldane Cengiz Seval ◽  
Sinem Civriz Bozdag ◽  
Selami Kocak Toprak ◽  
Meltem Kurt Yuksel ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Research Funding ◽  
Chronic Phase ◽  
Response Rates ◽  
Molecular Response ◽  
Optimal Response ◽  
Generic Group ◽  
Significant Difference ◽  
Generic Groups ◽  
Support Research

Introduction:Generic imatinib formulations are increasingly being used as more affordable alternatives worldwide and a few studies have evaluated the safety and efficacy of these formulations prospectively. We have retrospectively analyzed our CML cohort in terms of first line treatment of Glivec versus generic imatinib. This study aims to evaluate the safety and efficacy of generic imatinib products in chronic phase chronic myeloid leukemia as first line treatment. Methods:We have retrospectively analyzed our CML cohort from January 2000 to December 2018 treated with either Glivec or one of generic imatinib formulations. All of our patients (with 1 exception) were initiated imatinib in chronic phase in less than 56 days from diagnosis. All of our patients were followed in accordance with European Leukemia Net (ELN) 2013 recommendations and national hematology association CML guidelines and response definitions were applied according to ELN 2013 criteria. Event free survival (EFS) was defined as the time between treatment initiation and either loss of hematological response, progression to accelerated phase (AP) or blastic phase (BP), or death from any cause. Progression free survival was defined as the time between treatment initiation and transformation to AP, BP or death while on imatinib. For statistical analyses SPSS version 21.0 was used. All p values < 0.05 were considered statistically significant. Results:A total of 192 patients were analyzed comparing 102 (53.1 %) patients on Glivec with 90 patients on (476.9 %) generic formulations. 99 (51.6 %) were female patients. The median age of our population was median 46 years (14-88 years) for Glivec and median 51 years (19-79 years) for generic group (p=0.01). Risk stratifications according to Sokal, Hasford and ELTS scores were run for both Glivec and generic formulation groups. Most of the patients had low risk according to Sokal (137, 71.4%) and Hasford (116, 60.4 %) but intermediate risk according to ELTS (113, 58.9 %) scoring systems. There was no statistically significant difference in the gender distribution, Sokal, Hasford, ELTS scores and ECOG between the two groups. The median time to initiate imatinib treatment was 23.5 (1- 156) days for Glivec group and 13 (1- 51) days generic group (p< 0.05). But the late onset of the treatment was not associated with treatment failure or death. The median follow up was 119.8 (3.7- 250.5) months for Glivec group and 43.6 (2- 150) months for generic groups, respectively (p< 0.05). This difference might be explained by the fact that Glivec has been on the market for about two decades. Similar rates of grade> 2 hematological and non- hematological toxicity were seen in Glivec (4.9 %) and generic groups (3.3 %), respectively (p> 0.05). The rates of treatment failure at 3 months were significantly higher in generic formulation (6.7 %) group than Glivec (2.9 %) group (p< 0.05). Also, the rates of treatment failure at 6 months were significantly higher in generic formulation (3.3 %) group than Glivec (0.9 %) group (p< 0.05). Optimal molecular response rate at 3 months was 76.5 % (n=78) for Glivec and 32.2 % (n=29) for generic groups (p< 0.001). Also, optimal molecular response rate at 6 months was 69.6 % (n=71) for Glivec and 45.6 % (n=41) for generic groups (p= 0.01). Median EFS was found significantly higher for Glivec group compared to generic group (168 mos (95% CI: 159-177 mos) vs 74.6 mos (95% CI: 56-93); p<0.001) (Figure). Conclusion: We found that complete hematological response rates at 3 and 6 months were similar in both groups, but in early phase of treatment the optimal response rates of Glivec group was statistical significantly higher than generic group. Generic group presented with a lower rate of optimal response at 3 months but 13.4 % improvement in optimal response rates was observed at six months. No significant difference in safety concerns was observed between the groups. We recommend that these results from single center should be clarified in a prospective, randomized study including larger population. Figure Disclosures Özcan: AbbVie: Other: Travel support, Research Funding; MSD: Research Funding; Novartis: Research Funding; Amgen: Honoraria, Other: Travel support; BMS: Other: Travel support; Jazz: Other: Travel support; Sanofi: Other: Travel support; Abdi Ibrahim: Other: Travel support; Janssen: Other: Travel support, Research Funding; Bayer: Research Funding; Celgene Corporation: Research Funding, Travel support; Takeda: Honoraria, Other: Travel support, Research Funding; Archigen: Research Funding; Roche: Other: Travel support, Research Funding. Beksac:Celgene: Speakers Bureau; Janssen: Research Funding, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

On batch verification with group testing for vehicular communications

2011 ◽  
Vol 17 (8) ◽  
pp. 1851-1865 ◽  
Author(s):  
Chenxi Zhang ◽  
Pin-Han Ho ◽  
Janos Tapolcai
Keyword(s):  
Group Testing ◽  
Vehicular Communications ◽  
Batch Verification

Laonicespecies (Polychaeta, Spionidae) from the Whittard Canyon (NE Atlantic) with descriptions of two new species

2017 ◽  
Vol 97 (5) ◽  
pp. 961-973 ◽  
Author(s):  
Andrey Sikorski ◽  
Laetitia M. Gunton ◽  
Lyudmila Pavlova
Keyword(s):  
New Species ◽  
North Atlantic ◽  
Deep Water ◽  
The Body ◽  
Identification Key ◽  
The Other ◽  
Ne Atlantic ◽  
Two New Species ◽  
Generic Groups ◽  
Number Of Segments

Four species ofLaonice(Annelida: Spionidae) were collected from the lower bathyal depths (3300–3700 m) in the Whittard Canyon, NE Atlantic. Two are herewith described as new species:Laonice whittardensissp. nov. andLaonice nataesp. nov. The other two areLaonice blakeiSikorski & Jirkov, 1988 andLaonice magnacristataMaciolek, 2000.Laonice whittardensishas genital pouches appearing from chaetiger 3, prostomium free of peristomium and bidentate hooks.Laonice nataebelongs to the subgenusAppelloefianov. with prostomium distinct from the peristomium, more than two vertical rows of capillaries in several anterior chaetigers, genital pouches present on a limited number of segments or totally absent. However, the absence of pronounced anterior widening of the body together with anterior branchiae, which are remarkably (nearly twice) longer than the notopodial postchaetal lobes, the narrow lanceolate notopodial postchaetal lobes, the pronounced pointedness of all postchaetal lobes (both notopodial and neuropodial) in the anterior half of body at least, and absence of genital pouches and the size of the body all distinguishL. nataefrom other species belonging to this subgenus. An identification key to all nine known deep-water (>400 m depth)Laonicespecies in North Atlantic is given and four previously recognized sub-generic groups are formally named:Laonice, Sarsianasubgen. nov.,Appelloefiasubgen. nov.,Norgensiasubgen. nov.

scholarly journals A Large-Scale Concurrent Data Anonymous Batch Verification Scheme for Mobile Healthcare Crowd Sensing

2019 ◽  
Vol 6 (2) ◽  
pp. 1321-1330 ◽  
Author(s):  
Jingwei Liu ◽  
Huijuan Cao ◽  
Qingqing Li ◽  
Fanghui Cai ◽  
Xiaojiang Du ◽  
...  
Keyword(s):  
Large Scale ◽  
Batch Verification ◽  
Verification Scheme ◽  
Mobile Healthcare ◽  
Crowd Sensing
Sign in / Sign up

Export Citation Format

Share Document